TRDA - NASDAQ

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.

TRDAยทNASDAQ

$6.58

-0.90%
HealthcareBiotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$255.44M
EPS-3.4700
P/E Ratio-1.90
Earnings Date08/05/2026
Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. Fair Value Envelope

TRDA ยท NASDAQ

Our analysis suggests that TRDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.58, this represents a potential HIDDEN relative to our calculated worth for Entrada Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $6.58

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$110.9M
+ Cash & Equivalents$90.4M
Firm Value-$20.5M
- Debt$50.9M
Equity Value-$71.5M
/ Shares Outstanding38,037,079B
DCF Value-$2
OVERVALUED BY 129%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$64.3M
-$32.1M
-$16.1M
-$8.0M
-$4.0M
-$2.0M
-$1.0M
-$502.0K
-$251.0K
-$125.5K
Maintenance CapEx
-$104.1K
-$52.1K
-$26.0K
-$13.0K
-$6.5K
-$3.3K
-$1.6K
-$813
-$407
-$203
Owner Earnings
-$64.4M
-$32.2M
-$16.1M
-$8.0M
-$4.0M
-$2.0M
-$1.0M
-$502.8K
-$251.4K
-$125.7K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$59.6M
-$27.6M
-$12.8M
-$5.9M
-$2.7M
-$1.3M
-$586.8K
-$271.7K
-$125.8K
-$58.2K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TRDA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.